Ultrasound contrast developer Acusphere has received a warning letter from the Nasdaq Stock Market regarding its listing on the exchange, according to the Watertown, MA-based firm.
The July 14 letter states that Acusphere has not regained compliance with the exchange's minimum bid price of $1.00 per share as a requirement for continued listing. Unless the company requests a hearing before the Nasdaq Listing Qualifications Panel, it will be subject to delisting from the exchange's Global Market.
Acusphere plans to request a hearing, which it expects to be scheduled for late August or early September of this year. The company will request continued listing on either the Nasdaq Global Market or the Nasdaq Capital Market, based on its plan for demonstrating compliance with the applicable listing requirements. Nasdaq's Listing Qualifications Panel has the authority to grant Acusphere up to an additional 180 days from the date of the letter to comply with its standards, according to Acusphere.
Related Reading
FDA to review Acusphere's Imagify, July 1, 2008
Acusphere revenues flat for Q1 2008, May 9, 2008
Acusphere submits NDA for Imagify, April 29, 2008
Acusphere cuts annual net loss, March 17, 2008
Acusphere gets Nasdaq warning letter, January 14, 2008
Copyright © 2008 AuntMinnie.com
![Examples of ultrasound findings and techniques. (A) Images in a 39-year-old male patient with a mass in the left thigh. The mass is heterogeneous on the B-mode US image (compared with the patient in D) and showed increased microvascularity (superb microvascular imaging [SMI]) and shear-wave elastography (SWE) values. Undifferentiated pleomorphic sarcoma was diagnosed at biopsy (with pleomorphic rhabdomyosarcoma in surgical specimen). (B) Images in an 18-year-old male patient with a mass in the left leg. The mass is hypoechoic on the B-mode image, with no other findings suggestive of malignancy. The lesion is in contact with the cortex of the tibia, which is slightly irregular. CT revealed a doubtful anteromedial tibial erosion. The microvascular study demonstrated high vascularization, suggestive of malignancy. Periosteal Ewing sarcoma was diagnosed with both histologic and immunohistochemical confirmation. (C) Images in a 69-year-old female patient with a lump growing on the outside of the left leg. Multiple SWE examinations were performed (please note the high values obtained in the measurements, whereas the color map highlights the stiffness relative to adjacent tissues). SMI showed areas of increased vascularization to target for sampling. Undifferentiated spindle cell sarcoma was diagnosed at biopsy, with residual leiomyosarcoma in the surgical specimen after neoadjuvant therapy. (D) Images in a 56-year-old female patient with a mass in the right thigh. The mass is heterogeneous at both B-mode ultrasound (similar to patient A) and MRI (coronal T2-weighted spectral attenuated inversion recovery [SPAIR]; T1-weighted pre-contrast and postcontrast imaging), which even shows uptake after the administration of paramagnetic contrast material, which is traditionally suggestive of malignancy. Low values at SMI and elastography are suggestive of benignity. Spindle cell lipoma was diagnosed at biopsy, with atypical spindle cell lipomatous tumor in the surgical specimen.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/08/images-radiol250278fig2.APCFLSvX6p.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
